Share tips of the week
MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
Three to buy
Superdry
(The Sunday Telegraph) Superdry’s share price has tripled in less than a year. The group “is reinventing itself”: the products’ quality and style have been improved; it has “done some canny marketing” to appeal to a wider variety of customers; and managers have also concentrated on boosting internet sales, which grew by 34% in the year to April. “Progress on so many fronts reassures us that the share price recovery is built on solid foundations.” 394p
Trident Royalties
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
(The Mail on Sunday) Copper was trading at around $4,500 per tonne a year ago, but over the past few days its price has eclipsed $10,000 and it should keep rising. Metals are booming as economies begin to recover from Covid-19 and governments prepare to increase spending on infrastructure. Trident’s business is mining-royalty finance, whereby firms lend money to miners and receive a percentage of their revenues in return. Trident has already signed seven royalty agreements on iron, copper, gold and lithium. An eighth transaction “is expected imminently”. The variety of metals tempers Trident’s overall exposure to price fluctuations. 34p
Avon Rubber
(Investors’ Chronicle) Protective equipment specialist Avon Rubber’s shares reached a record peak in December, but nosedived two weeks later after it announced delays to two of its US contracts. But the firm has since released two positive trading updates, and has reported “positive momentum” in its second quarter. The group expects sales for the six months to 31 March to jump by two-fifths year-on-year to $122m, and it has “continued to secure more orders”. 3,328p
Three to sell
Calyxt
(Nasdaq) Calyxt uses gene-editing technology to alter living plant cells. The company took nine years to launch its first product: soybean seeds producing cooking oil that doesn’t degrade as fast as regular soybean oil. But it hasn’t been able to sell the seeds at a “viable price” and is still a “long way from earning any money for its investors”. The firm has several modified agricultural products in its pipeline, but investors should wait for proof that it can sell at least one of them at a profit. Avoid. $4.34
Peloton
(Forbes) Peloton shares have dropped by 50% since peaking in December, but the stock is still not a bargain. The firm has had to recall its treadmill, Tread+, after the US Consumer Product Safety Commission urged users with children and pets to stop using it, citing dozens of injuries and at least one death. The recall, which CEO John Foley dragged his feet over, “introduces considerable uncertainty into its revenue growth”. Reopening gyms, meanwhile, may dent demand for Peloton’s exercise bikes. Avoid. $83.81
EKF Diagnostics
(The Sunday Times) EKF Diagnostics specialises in “point of care” tests that allow physicians to find out in real time whether patients are suffering from conditions like anaemia, diabetes or sepsis. It has thrived throughout the pandemic as it makes sample collection kits that keep the virus “inactivated” in the tube, avoiding contamination. It supplies Public Health England and the Irish government. But can it keep up the momentum? Covid-19-related sales accounted for 40% of last year’s revenue, but beyond that “sales have fallen short”. Investors should “take profits”. 70p
...and the rest
Investors’ Chronicle
Fast-fashion retailer Boohoo has benefited from high street closures and a rise in online sales. It is investing heavily in future growth but has still managed to bolster its net cash. It looks set to “continue as an e-commerce fashion winner”. Hold (317p). WHSmith struggled throughout the pandemic but it has announced over 100 new travel stores, and much of that new business stems from North America, which is opening up “far quicker than the UK”. Hold (1,827p).
The Daily Telegraph
There are still plenty of bargains in the British stockmarket, especially for those “willing to be brave and invest in businesses and industries that remain out of favour”. Shares in International Airlines Group are trading at 210p, down from 400p, but it “could return to its pre-Covid-19 profit margin levels as soon as 2023”.
The Mail on Sunday
Increased government spending on infrastructure bodes well for Hill & Smith, the UK’s leading supplier of road-safety barriers. Though its business dipped in 2020, analysts expect figures to bounce back this year and next, with profits of £75m forecast for 2021, rising to £82m in 2022. Buy (1,578p).
Shares
Shares in medical-products firm Convatec have picked up after a slow start to the year. Sales rose by 8.7% in the first quarter of 2021 and the outlook for the remainder of 2021 is encouraging. Buy (205p). Eyewear frames designer Inspecs’ shares are up by 50% in five months. They look poised to keep profiting from pent-up demand and the overall market recovery. Keep buying (404p).
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
-
Cash in on the growth prospects of Europe's companies
Opinion Marcel Stötzel, co-portfolio manager of the Fidelity European Trust, selects three stocks
By Marcel Stotzel Published
-
Is the AI boom another dotcom bubble?
25 years on from the dotcom bubble bursting, is it time for investors to consider the sustainability of the AI boom in the stock market?
By Dan McEvoy Published
-
Cash in on the growth prospects of Europe's companies
Opinion Marcel Stötzel, co-portfolio manager of the Fidelity European Trust, selects three stocks
By Marcel Stotzel Published
-
Why CEOs deserve a pay rise
Opinion The CEOs of big companies often come under fire for being grossly overpaid. But the truth, as per some economists, is the opposite. Do they merit a pay rise?
By Stuart Watkins Published
-
Rolls-Royce stock jumps 15% – could it climb further?
Aircraft-engine group Rolls-Royce’s CEO has been hailed as a hero for spearheading the firm’s recovery. And the future looks bright, says Matthew Partridge
By Dr Matthew Partridge Published
-
The power of private markets
Interview Helen Steers, co-manager of the Pantheon International investment trust, tells MoneyWeek about the vast array of compelling opportunities in private equity
By Andrew Van Sickle Published
-
Vertex Pharmaceuticals is an uncommon opportunity in rare diseases
Vertex Pharmaceuticals operates in a profitable subsector and is poised for further success
By Dr Mike Tubbs Published
-
Global investors have overlooked these top tips in emerging markets
Opinion Chris Tennant, co-portfolio manager of Fidelity Emerging Markets, picks three attractive companies in emerging markets
By Chris Tennant Published
-
King Coal has not been dethroned yet — should you buy?
The demand for coal is only growing, yet investors don’t seem to want to take advantage of the opportunity, says Rupert Hargreaves
By Rupert Hargreaves Published
-
It’s time to start buying Europe again, says Merryn Somerset Webb
Opinion Europe's stocks are cheap and the economic backdrop is starting to look cheerier, says Merryn Somerset Webb
By Merryn Somerset Webb Published